FDA Advisory Panel Recommends Against Approval Of Novartis Heart Failure …

FDA Advisory Panel Recommends Against Approval Of Novartis Heart Failure …

The FDA's Cardiovascular and Renal Drugs Advisory Committee voted unanimously (11-0) against approval of the biologics license application (BLA) for serelaxin (proposed trade name Reasanz). The novel drug from Novartis was intended to be used in …

9
Like
Save

Comments

Write a comment

*